Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100932 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00100932 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 106 participants.
The verdict
NCT00100932, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a study of E7389 in patients with recurrent and/or metastatic Non-Small-Cell Lung Cancer (NSCLC) who progressed during or after treatment with a platinum agent and another chemotherapy.
Interventions
- DRUG E7389 28 Day Cycle
- DRUG E7389 21 Day Cycle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100932
The ClinicalTrials.gov registry entry for NCT00100932 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which E7389 28 Day Cycle is the first listed.
NCT00100932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100932 about?
NCT00100932 is a clinical study titled "Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy". This is a study of E7389 in patients with recurrent and/or metastatic Non-Small-Cell Lung Cancer (NSCLC) who progressed during or after treatment with a platinum agent and another chemotherapy.
What is the current status of trial NCT00100932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2004-12.
What interventions are being tested in trial NCT00100932?
The interventions under investigation include: E7389 28 Day Cycle (DRUG), E7389 21 Day Cycle (DRUG).
Who is sponsoring clinical trial NCT00100932?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.